PDF(Pubmed)
Abstract：
Vascular endothelial growth factor（VEGF）, fibroblast growth factor（FGF）, nerve growth factor（NGF）, epidermal growth factor and interferon are important endogenous proteins that regulate cell proliferation, differentiation and regeneration. Biological products targeting growth factors are used in the treatment of ocular diseases such as wet age-related macular degeneration, corneal injury and neurotrophic keratitis. Anti-VEGF drugs can regulate the proliferation of vascular endothelia, reduce the edema and exudation of retinal tissue，which are the main therapeutic agents for wet age-related macular degeneration and diabetic retinopathy. The basic FGF (b-FGF) can promote the proliferation, differentiation, and migration of corneal epithelial cells, accelerating the healing of the corneal injury and reduces corneal inflammation；and bovine b-FGF has been approved for the treatment of corneal injuries. The NGF promotes the growth, development, and differentiation of central and peripheral neurons, thus accelerating the repair of nerve damage；and the European Medicines Agency approved the use of nerve growth factor for the treatment of neurotrophic keratitis in 2017. Recent clinical studies show that patients with moderate or severe neurotrophic keratitis achieved complete corneal healing following 8 weeks of NGF therapy. Epidermal growth factor derivative eye drops have been approved for the treatment of corneal epithelial injuries. Recombinant human interferon has been clinically used in the treatment of ocular viral infections. This article reviews the research progress in the development of new cell growth factor drugs for the treatment of ophthalmic diseases, to provide insights for expanding the application of cell growth factors in ophthalmology.
摘要：
血管内皮生长因子（VEGF）,成纤维细胞生长因子（FGF）,神经生长因子（NGF）,表皮生长因子和干扰素是调节细胞增殖的重要内源性蛋白,分化和再生。针对生长因子的生物制品用于治疗眼病，如湿性年龄相关性黄斑变性，角膜损伤和神经营养性角膜炎。抗VEGF药物可以调节血管内皮细胞的增殖,减轻视网膜组织的水肿和渗出，是湿性年龄相关性黄斑变性和糖尿病性视网膜病变的主要治疗药物。碱性FGF(b-FGF)可以促进细胞增殖,分化,和角膜上皮细胞的迁移，加速角膜损伤的愈合，减少角膜炎症；牛b-FGF已被批准用于角膜损伤的治疗。NGF促进了生长，发展,以及中枢和外周神经元的分化，从而加速神经损伤的修复；2017年欧洲药品管理局批准使用神经生长因子治疗神经营养性角膜炎。最近的临床研究表明，患有中度或重度神经营养性角膜炎的患者在NGF治疗8周后实现了完全的角膜愈合。表皮生长因子衍生物滴眼液已被批准用于治疗角膜上皮损伤。重组人干扰素已在临床上用于治疗眼部病毒感染。本文就治疗眼科疾病的新型细胞生长因子药物的研究进展作一综述。为扩大细胞生长因子在眼科的应用提供见解。
